Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-α
Phase II Cladribine Add-on to Interferon-beta (IFN-b) Therapy in MS Subjecs With Active Disease (ONWARD)
Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.
Receptos Reports Positive Phase 2 Results for TOUCHSTONE Trial of RPC1063 in Ulcerative Colitis
Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota.
Epigenetic mechanisms in multiple sclerosis and the major histocompatibility complex (MHC).
Specific peripheral B cell tolerance defects in patients with multiple sclerosis.
A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (LIBRETTO)
A complex role of herpes viruses in the disease process of multiple sclerosis.
Testing for urinary tract colonisation before high-dose corticosteroid treatment in acute multiple sclerosis relapses: prospective algorithm validation.
US top court denies Israel's Teva Pharmaceuticals stay in Copaxone patent fight
Emerging roles of endothelial cells in multiple sclerosis pathophysiology and therapy.
BTG Commences Phase IIa Study of Multiple Sclerosis
Roche's MabThera approved for two vasculitis indications in UK
Epigenetic changes in patients with multiple sclerosis.
Clinical profile of malay children with optic neuritis.
Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer.
Significant Percentage of MS Patients Receiving Alemtuzumab in Genzyme’s Phase 2 Trial Remain Free of Clinically Active Disease
Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis.
Teva to present positive data for glatiramer acetate 40 mg/1 ml given three times weekly for relapsing-remitting MS
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
Teva Presents Data Comparing Early Treatment with COPAXONE® 40 mg/mL to Delayed Start Treatment at 67th American Academy of Neurology (AAN) Annual Meeting in Washington, D.C.
Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies.
Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome.
Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment.

Pages